Compass Therapeutics vs ImageneBio
CMPX and IMA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CMPX and IMA compare
Compass Therapeutics is the larger company, worth 3.5 times as much as ImageneBio ($150M against $42.2M).
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CMPX | IMA |
|---|---|---|
| Size and price | ||
| Market cap | $150M | $42.2M |
| Share price | $0.830 | $3.72 |
| Change, 1 year | −80.6% | −54.6% |
| Change, 5 years | −76.1% | −98.0% |
| Beta (5Y) | 1.27 | 1.18 |
| Employees | 39 | 15 |
| StockData Score | ||
| Total score | 7 | 7 |
| Valuation score | 1 | 1 |
| Growth score | 0 | 0 |
| Performance score | 1 | 1 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 1.0× | 0.3× (better) |
| FCF yield | −41.4% | – |
| Growth | ||
| Revenue growth, 5Y average | – | −38.6% |
| Profitability | ||
| Return on equity | −49.0% | −32.3% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 6.79 | 16.17 (better) |
| Altman Z-score | −2.02 | −0.99 (better) |
| Piotroski F-score | 3 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 92.0% | 54.9% |
| Held by insiders | 26.3% | 52.9% |
| Insider net buying, 12 months | $96.8K (better) | $78.5K |
| Short interest, % of float | 30.7% | 0.86% |
Go deeper
- CMPX stock overview
- CMPX income statement
- CMPX valuation and score
- IMA stock overview
- IMA income statement
- IMA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.